Sarepta Therapeutics, Inc. (SRPT)
$
16.65
-0.51 (-3.06%)
Key metrics
Financial statements
Free cash flow per share
-3.0291
Market cap
1.7 Billion
Price to sales ratio
0.7952
Debt to equity
0.9114
Current ratio
2.3171
Income quality
0.2880
Average inventory
996 Million
ROE
-0.5752
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for rare diseases. The diluted EPS is -$7.13 accounting for potential share dilution. The financial data pertains to the fiscal year 2025 reflecting the overall performance of the company. The income before tax ratio is -0.32 which showcases the pre-tax margin and operational efficiency of Sarepta. Furthermore, the cost of revenue for the company is $881,504,000.00 highlighting its production and operational expenses. Despite these costs, the company earned an interest income of $19,569,000.00 showcasing its financial investments and ability to generate additional revenue streams. Sarepta offers the EXONDYS 51 injection and VYONDYS 53 for the treatment of Duchenne muscular dystrophy in patients with specific confirmed mutations in the dystrophin gene. The company is also progressing in developing AMONDYS 45, SRP-5051, SRP-9001, and SRP-9003, thereby solidifying its commitment to addressing rare genetic diseases through innovative therapies. Currently, the stock is reasonably priced at $17.43 appealing to a broad range of investors. This attractiveness is further supported by an average trading volume of 2,602,642.00 indicating moderate liquidity for potential and existing shareholders. With a mid-range market capitalization of $1,748,079,704.00 the company is a steady performer in its sector. It is a key player in the biotechnology industry, contributing significantly to the overall market landscape, while also driving innovation and growth in the healthcare sector. Through its collaborations with multiple organizations, Sarepta continues to enhance its research and development capabilities, positioning itself as a leader in genetic therapies and a vital contributor to advancements aimed at treating rare diseases.
Is Sarepta Therapeutics, Inc. (SRPT) a good investment?
Investing in Sarepta Therapeutics, Inc. (SRPT) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Sarepta Therapeutics, Inc. (SRPT)'s stock forecast?
Analysts predict Sarepta Therapeutics, Inc. stock to fluctuate between $10.42 (low) and $76.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Sarepta Therapeutics, Inc.'s market capitalization?
As of 2026-03-19, Sarepta Therapeutics, Inc.'s market cap is $1,748,079,704, based on 104,989,772 outstanding shares.
How does Sarepta Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Sarepta Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Sarepta Therapeutics, Inc. (SRPT) stock?
To buy Sarepta Therapeutics, Inc. (SRPT) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SRPT. Place an order (Market, Limit, etc.).
What is the best time to invest in Sarepta Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Sarepta Therapeutics, Inc. stock ever split?
Sarepta Therapeutics, Inc.'s last stock split was 1:6 on 2012-07-12.
How did Sarepta Therapeutics, Inc. perform in the last earnings report?
Revenue: $2,198,237,000 | EPS: -$7.13 | Growth: -388.66%.
Where can I find Sarepta Therapeutics, Inc.'s investor relations reports?
Visit https://www.sarepta.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Sarepta Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Sarepta Therapeutics, Inc. stock?
All-time high: $173.25 (2024-06-21) | All-time low: $10.42 (2025-07-24).
What are the key trends affecting Sarepta Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided an update on its ongoing regulatory interactions with the U.S. Food and Drug Administration (FDA) regarding AMONDYS 45® (casimersen) and VYONDYS 53® (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD). Sarepta requested a meeting with FDA to discuss submitting supplemental new drug applications (sNDA) seeking conversion of the ac.
zacks.com
Sarepta gains as enrollment begins in a new ENDEAVOR study cohort testing a sirolimus regimen to improve Elevidys safety in DMD patients.
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced screening and enrollment are underway in Cohort 8 of ENDEAVOR (Study 9001-103). The purpose of Cohort 8 is to assess prophylactic sirolimus treatment as part of an enhanced safety protocol during treatment with ELEVIDYS (delandistrogene moxeparvovec-rokl) in non-ambulant individuals with Duchenne muscular dystrophy. Data from Cohort 8 will be u.
seekingalpha.com
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
defenseworld.net
AXQ Capital LP decreased its position in Sarepta Therapeutics, Inc. (NASDAQ: SRPT) by 72.8% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,619 shares of the biotechnology company's stock after selling 39,088 shares during the quarter. AXQ
zacks.com
SRPT posts a wider Q4 loss as Elevidys sales tumble, but revenues top estimates and 2026 guidance outlines a cautious recovery path.
reuters.com
Sarepta Therapeutics CEO Douglas Ingram has decided to step down by the end of 2026 or upon the appointment of his replacement, the company said in a regulatory filing.
seekingalpha.com
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
businesswire.com
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2025 financial results. The event will be webcast live under the investor relations section of Sarepta's website a.
zacks.com
SRPT jumps nearly 8% after Elevidys shows sustained motor gains and slower progression three years post-dose in the phase III EMBARK DMD study.
See all news
